Compass
AI Equity Research
Start free for 3 days
AI Equity Research · Healthcare

Evolent Health, Inc. (EVH)

AI stock analysis · Health Information Services · Last analyzed Aug 18, 2026

Compass Score
3.0/5
Call
Hold
Price
$4.41
AI Target
$5.62 +27.3%
AI Analyst Summary

Evolent Health is executing a high-growth specialty care management strategy, delivering 46.9% YoY revenue growth driven by expanding oncology and complex condition management contracts with health plans. The forward P/E of 11.4x is compelling if management converts top-line momentum into sustained profitability, and the broad analyst Buy consensus reflects confidence in that trajectory. The key risk is that the company remains loss-making, and any deterioration in managed care utilization trends or contract losses could pressure both revenue and the path to profitability.

Catalysts
Risks
Fundamentals
Pe N/A (loss-making) · 2.0/5
No trailing P/E available as the company is currently loss-making. Forward P/E of 11.4x is attractive if the path to profitability materializes, but the absence of current earnings warrants caution.
Peg 1.93 · 3.0/5
PEG of 1.93 is moderate — not cheap, but not egregiously expensive. Sits between the 1.0 value threshold and the 3.0 danger zone, landing in neutral territory given the high revenue growth backdrop.
Analyst Rating Buy consensus (1.7) · 4.0/5
13 analysts covering the stock with a consensus of 1.7, reflecting 12 Buy and 3 Hold ratings and zero Sells. Strong bullish skew supports a score of 4, though not quite at the 5-level threshold of 1.0–1.5.
Earnings Trend Revenue +46.9% YoY; EPS N/A · 3.0/5
Revenue growth of 46.9% YoY is impressive and signals strong demand for Evolent's oncology and specialty care management platform. However, the absence of positive EPS and lack of a clear YoY earnings growth figure limits this score to neutral — top-line momentum must convert to bottom-line delivery.
Price Target Beat 3 of 4 quarters · 3.0/5
EPS beat rate of 3 out of 4 recent quarters is in line with expectations — decent consistency but not exceptional. Only 4 quarters of data available, so scored conservatively at 3.
Management Moderate execution · 3.0/5
Management has driven exceptional revenue growth and maintained reasonable EPS beat consistency, but the company remains unprofitable. Analyst confidence is high (12 Buys), suggesting credibility, but capital allocation and margin discipline are still unproven at scale.
See the full picture
Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →
No credit card. Then $9/month. Cancel anytime.
How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.